{"name":"Celgene","slug":"celgene","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":13003000000,"revenueGrowth":273.3,"grossMargin":0,"rdSpend":121200000,"netIncome":4046000000,"cash":35480000000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[{"name":"Reblozyl","genericName":"LUSPATERCEPT","slug":"luspatercept","revenue":2327000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2019-01-01","label":"Reblozyl first approved","drug":"Reblozyl","drugSlug":"luspatercept","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-02-28","label":"REBLOZYL Phase 3 readout (Myelodysplastic Syndromes)","drug":"REBLOZYL","drugSlug":"luspatercept-aamt","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-12-30","label":"REBLOZYL Phase 3 readout (Myelodysplastic Syndromes)","drug":"REBLOZYL","drugSlug":"luspatercept-aamt","type":"phase3_readout","sentiment":"neutral"},{"date":"2030-03-11","label":"REBLOZYL Phase 3 readout (Myelodysplastic Syndromes)","drug":"REBLOZYL","drugSlug":"luspatercept-aamt","type":"phase3_readout","sentiment":"neutral"},{"date":"2032-08-18","label":"REBLOZYL Phase 3 readout (Myeloproliferative Disorders, Myelofibrosis)","drug":"REBLOZYL","drugSlug":"luspatercept-aamt","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":2327000000,"percentOfTotal":100,"drugCount":13,"colorKey":"oncology","drugs":[{"name":"Reblozyl","genericName":"LUSPATERCEPT","slug":"luspatercept","indication":"Myelodysplastic syndrome","status":"marketed","revenue":2327000000},{"name":"Conventional Care Regimen","genericName":"Conventional Care Regimen","slug":"conventional-care-regimen","indication":"Other","status":"phase_3"},{"name":"ABI-008","genericName":"ABI-008","slug":"abi-008","indication":"Other","status":"phase_1"},{"name":"AG-221","genericName":"AG-221","slug":"ag-221","indication":"Other","status":"phase_3"},{"name":"AVL-292","genericName":"AVL-292","slug":"avl-292","indication":"Other","status":"phase_1"},{"name":"Duravalumab","genericName":"Duravalumab","slug":"duravalumab","indication":"Other","status":"phase_2"},{"name":"Investigators choice single agent","genericName":"Investigators choice single agent","slug":"investigators-choice-single-agent","indication":"Other","status":"phase_2"},{"name":"Lenalomide","genericName":"Lenalomide","slug":"lenalomide","indication":"Other","status":"phase_2"},{"name":"Lymphodepleting","genericName":"Lymphodepleting","slug":"lymphodepleting","indication":"Other","status":"discontinued"},{"name":"NPI-0052 on Days 1, 4, 8, 11 every 21 days","genericName":"NPI-0052 on Days 1, 4, 8, 11 every 21 days","slug":"npi-0052-on-days-1-4-8-11-every-21-days","indication":"Other","status":"phase_1"},{"name":"REBLOZYL","genericName":"LUSPATERCEPT-AAMT","slug":"luspatercept-aamt","indication":"Myelodysplastic syndrome","status":"marketed"},{"name":"RPC4046","genericName":"RPC4046","slug":"rpc4046","indication":"Other","status":"phase_2"},{"name":"Rasigiline","genericName":"Rasigiline","slug":"rasigiline","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":19,"colorKey":"cardiovascular","drugs":[{"name":"Abraxane (Induction)","genericName":"Abraxane (Induction)","slug":"abraxane-induction","indication":"Metastatic non-small cell lung cancer (induction therapy)","status":"phase_3"},{"name":"Abraxane (Maintenance)","genericName":"Abraxane (Maintenance)","slug":"abraxane-maintenance","indication":"Metastatic non-small cell lung cancer (maintenance therapy)","status":"phase_3"},{"name":"BMS-986365","genericName":"BMS-986365","slug":"bms-986365","indication":"Acute myeloid leukemia (AML) with NPM1 mutation or MLL rearrangement","status":"phase_3"},{"name":"BMS-986368","genericName":"BMS-986368","slug":"bms-986368","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"CC-122","genericName":"CC-122","slug":"cc-122","indication":"Multiple myeloma","status":"phase_2"},{"name":"CC-2001","genericName":"CC-2001","slug":"cc-2001","indication":"Relapsed or refractory multiple myeloma","status":"phase_2"},{"name":"CC-220","genericName":"CC-220","slug":"cc-220","indication":"Systemic lupus erythematosus","status":"phase_2"},{"name":"CC-5013 plus dexamethasone","genericName":"CC-5013 plus dexamethasone","slug":"cc-5013-plus-dexamethasone","indication":"Multiple myeloma (newly diagnosed and relapsed/refractory)","status":"phase_3"},{"name":"CC-93538","genericName":"CC-93538","slug":"cc-93538","indication":"Multiple myeloma","status":"phase_3"},{"name":"CDC-501","genericName":"CDC-501","slug":"cdc-501","indication":"Multiple myeloma (phase 2 development)","status":"phase_2"},{"name":"Carboplatin (Induction)","genericName":"Carboplatin (Induction)","slug":"carboplatin-induction","indication":"Ovarian cancer (induction therapy)","status":"phase_3"},{"name":"Istodax","genericName":"Istodax","slug":"istodax","indication":"Peripheral T-cell lymphoma","status":"marketed"},{"name":"JCAR017","genericName":"JCAR017","slug":"jcar017","indication":"Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)","status":"phase_2"},{"name":"Lenalidomide and low-dose dexamethasone","genericName":"Lenalidomide and low-dose dexamethasone","slug":"lenalidomide-and-low-dose-dexamethasone","indication":"Multiple myeloma (newly diagnosed and relapsed/refractory)","status":"phase_3"},{"name":"Low-dose cytarabine (LDAC)","genericName":"Low-dose cytarabine (LDAC)","slug":"low-dose-cytarabine-ldac","indication":"Acute myeloid leukemia (AML) in elderly or unfit patients","status":"phase_3"},{"name":"Oral Fedratinib","genericName":"Oral Fedratinib","slug":"oral-fedratinib","indication":"Myeloproliferative neoplasm","status":"phase_2"},{"name":"Predinsone/Prednisolone","genericName":"Predinsone/Prednisolone","slug":"predinsone-prednisolone","indication":"Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis)","status":"phase_3"},{"name":"bb2121","genericName":"bb2121","slug":"bb2121","indication":"Relapsed or refractory multiple myeloma","status":"phase_3"},{"name":"low-dose dexamethasone","genericName":"low-dose dexamethasone","slug":"low-dose-dexamethasone","indication":"Multiple myeloma (in combination with lenalidomide and bortezomib)","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"Placebo to interferon beta-1a","genericName":"Placebo to interferon beta-1a","slug":"placebo-to-interferon-beta-1a","indication":"Relapsing-remitting multiple sclerosis","status":"phase_3"},{"name":"RPC1063","genericName":"RPC1063","slug":"rpc1063","indication":"Relapsing forms of multiple sclerosis","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"Placebo to ozanimod","genericName":"Placebo to ozanimod","slug":"placebo-to-ozanimod","indication":"Ulcerative colitis","status":"phase_3"},{"name":"Pneumococcal polysaccharide vaccine","genericName":"Pneumococcal polysaccharide vaccine","slug":"pneumococcal-polysaccharide-vaccine","indication":"Prevention of invasive pneumococcal disease in adults ≥50 years","status":"marketed"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ACE-011","genericName":"ACE-011","slug":"ace-011","indication":"Myelodysplastic syndromes with anemia","status":"phase_2"}]}],"pipeline":[{"name":"Reblozyl","genericName":"LUSPATERCEPT","slug":"luspatercept","phase":"marketed","mechanism":"Reblozyl works by binding to growth/differentiation factor 11, promoting the maturation of red blood cells.","indications":["Myelodysplastic syndrome","beta Thalassemia"],"catalyst":""},{"name":"Conventional Care Regimen","genericName":"Conventional Care Regimen","slug":"conventional-care-regimen","phase":"phase_3","mechanism":"Conventional Care Regimen is a standard-of-care treatment protocol rather than a single drug, typically consisting of established therapeutic agents used as a comparator arm in clinical trials.","indications":[],"catalyst":""},{"name":"ABI-008","genericName":"ABI-008","slug":"abi-008","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ACE-011","genericName":"ACE-011","slug":"ace-011","phase":"phase_2","mechanism":"ACE-011 is an activin receptor type IIA ligand trap that inhibits activin signaling to promote erythropoiesis and increase hemoglobin levels.","indications":["Myelodysplastic syndromes with anemia","Chronic kidney disease-related anemia"],"catalyst":""},{"name":"AG-221","genericName":"AG-221","slug":"ag-221","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AVL-292","genericName":"AVL-292","slug":"avl-292","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Abraxane (Induction)","genericName":"Abraxane (Induction)","slug":"abraxane-induction","phase":"phase_3","mechanism":"Abraxane is a nanoparticle albumin-bound paclitaxel that stabilizes microtubules to inhibit cell division and induce apoptosis in cancer cells.","indications":["Metastatic non-small cell lung cancer (induction therapy)","Metastatic breast cancer","Pancreatic cancer"],"catalyst":""},{"name":"Abraxane (Maintenance)","genericName":"Abraxane (Maintenance)","slug":"abraxane-maintenance","phase":"phase_3","mechanism":"Abraxane is a nanoparticle albumin-bound paclitaxel that stabilizes microtubules to inhibit cell division and induce apoptosis in cancer cells.","indications":["Metastatic non-small cell lung cancer (maintenance therapy)","Metastatic breast cancer","Pancreatic cancer"],"catalyst":""},{"name":"BMS-986365","genericName":"BMS-986365","slug":"bms-986365","phase":"phase_3","mechanism":"BMS-986365 is a selective inhibitor of menin that disrupts the interaction between menin and mixed-lineage leukemia (MLL) proteins, restoring normal gene expression in leukemic cells.","indications":["Acute myeloid leukemia (AML) with NPM1 mutation or MLL rearrangement","Mixed-lineage leukemia (MLL)-rearranged acute leukemia"],"catalyst":""},{"name":"BMS-986368","genericName":"BMS-986368","slug":"bms-986368","phase":"phase_2","mechanism":"BMS-986368 is an anti-PD-1 monoclonal antibody.","indications":["Non-small cell lung cancer","Melanoma"],"catalyst":""},{"name":"CC-122","genericName":"CC-122","slug":"cc-122","phase":"phase_2","mechanism":"CC-122 is a selective inhibitor of the immunoproteasome.","indications":["Multiple myeloma"],"catalyst":""},{"name":"CC-2001","genericName":"CC-2001","slug":"cc-2001","phase":"phase_2","mechanism":"CC-2001 is a histone deacetylase inhibitor.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"CC-220","genericName":"CC-220","slug":"cc-220","phase":"phase_2","mechanism":"CC-220 is a small molecule that modulates the activity of cereblon, an E3 ubiquitin ligase, leading to the degradation of specific proteins involved in inflammation and immune responses.","indications":["Systemic lupus erythematosus","Multiple myeloma"],"catalyst":""},{"name":"CC-5013 plus dexamethasone","genericName":"CC-5013 plus dexamethasone","slug":"cc-5013-plus-dexamethasone","phase":"phase_3","mechanism":"CC-5013 (lenalidomide) is an immunomodulatory agent that enhances T-cell proliferation and cytokine production while dexamethasone provides corticosteroid-mediated anti-inflammatory and anti-proliferative effects.","indications":["Multiple myeloma (newly diagnosed and relapsed/refractory)"],"catalyst":""},{"name":"CC-93538","genericName":"CC-93538","slug":"cc-93538","phase":"phase_3","mechanism":"CC-93538 is a cereblon E3 ligase modulator (CELMoD) that degrades Ikaros and Ikzf3 proteins to enhance T-cell proliferation and anti-tumor immunity.","indications":["Multiple myeloma","Lymphoma"],"catalyst":""},{"name":"CDC-501","genericName":"CDC-501","slug":"cdc-501","phase":"phase_2","mechanism":"CDC-501 is a cereblon E3 ligase modulator that degrades specific proteins involved in immune regulation and cell proliferation.","indications":["Multiple myeloma (phase 2 development)"],"catalyst":""},{"name":"Carboplatin (Induction)","genericName":"Carboplatin (Induction)","slug":"carboplatin-induction","phase":"phase_3","mechanism":"Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing cancer cell replication and inducing cell death.","indications":["Ovarian cancer (induction therapy)","Non-small cell lung cancer","Small cell lung cancer","Head and neck cancer","Testicular cancer"],"catalyst":""},{"name":"Duravalumab","genericName":"Duravalumab","slug":"duravalumab","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Investigators choice single agent","genericName":"Investigators choice single agent","slug":"investigators-choice-single-agent","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Istodax","genericName":"Istodax","slug":"istodax","phase":"marketed","mechanism":"Bromodomain-containing protein 4, Histone deacetylase 3/NCoR1, Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2)","indications":["Peripheral T-cell lymphoma","Primary cutaneous T-cell lymphoma"],"catalyst":""},{"name":"JCAR017","genericName":"JCAR017","slug":"jcar017","phase":"phase_2","mechanism":"JCAR017 is a CD19-directed CAR T-cell therapy designed to target and eliminate CD19-positive B cells.","indications":["Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)"],"catalyst":""},{"name":"Lenalidomide and low-dose dexamethasone","genericName":"Lenalidomide and low-dose dexamethasone","slug":"lenalidomide-and-low-dose-dexamethasone","phase":"phase_3","mechanism":"Lenalidomide enhances immune cell activity and has anti-angiogenic and anti-proliferative effects, while dexamethasone provides anti-inflammatory and immunosuppressive activity to reduce myeloma cell growth.","indications":["Multiple myeloma (newly diagnosed and relapsed/refractory)","Light chain myeloma"],"catalyst":""},{"name":"Lenalomide","genericName":"Lenalomide","slug":"lenalomide","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Low-dose cytarabine (LDAC)","genericName":"Low-dose cytarabine (LDAC)","slug":"low-dose-cytarabine-ldac","phase":"phase_3","mechanism":"Low-dose cytarabine is a nucleoside analog that inhibits DNA synthesis by incorporating into DNA and blocking cell division, primarily affecting rapidly dividing hematopoietic cells.","indications":["Acute myeloid leukemia (AML) in elderly or unfit patients","Myelodysplastic syndrome (MDS)"],"catalyst":""},{"name":"Lymphodepleting","genericName":"Lymphodepleting","slug":"lymphodepleting","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"NPI-0052 on Days 1, 4, 8, 11 every 21 days","genericName":"NPI-0052 on Days 1, 4, 8, 11 every 21 days","slug":"npi-0052-on-days-1-4-8-11-every-21-days","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Oral Fedratinib","genericName":"Oral Fedratinib","slug":"oral-fedratinib","phase":"phase_2","mechanism":"JAK2 inhibitor","indications":["Myeloproliferative neoplasm"],"catalyst":""},{"name":"Placebo to interferon beta-1a","genericName":"Placebo to interferon beta-1a","slug":"placebo-to-interferon-beta-1a","phase":"phase_3","mechanism":"Interferon beta-1a activates interferon signaling pathways to modulate immune responses and reduce inflammatory activity.","indications":["Relapsing-remitting multiple sclerosis","Secondary progressive multiple sclerosis"],"catalyst":""},{"name":"Placebo to ozanimod","genericName":"Placebo to ozanimod","slug":"placebo-to-ozanimod","phase":"phase_3","mechanism":"Ozanimod is a selective sphingosine-1-phosphate (S1P) receptor modulator that reduces lymphocyte egress from lymphoid tissues, decreasing circulating lymphocytes and inflammatory cell infiltration into affected tissues.","indications":["Ulcerative colitis","Crohn's disease"],"catalyst":""},{"name":"Pneumococcal polysaccharide vaccine","genericName":"Pneumococcal polysaccharide vaccine","slug":"pneumococcal-polysaccharide-vaccine","phase":"marketed","mechanism":"Pneumococcal polysaccharide vaccine stimulates the immune system to produce antibodies against multiple serotypes of Streptococcus pneumoniae, providing protection against pneumococcal infection.","indications":["Prevention of invasive pneumococcal disease in adults ≥50 years","Prevention of pneumococcal pneumonia, bacteremia, and meningitis in at-risk populations","Immunization of patients with chronic conditions (COPD, cardiovascular disease, diabetes) and immunocompromised individuals"],"catalyst":""},{"name":"Predinsone/Prednisolone","genericName":"Predinsone/Prednisolone","slug":"predinsone-prednisolone","phase":"phase_3","mechanism":"Prednisone/prednisolone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","indications":["Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis)","Hematologic malignancies (as adjunctive therapy in lymphomas and leukemias)","Allergic and respiratory conditions (asthma, COPD exacerbations)","Adrenal insufficiency and other endocrine disorders"],"catalyst":""},{"name":"REBLOZYL","genericName":"LUSPATERCEPT-AAMT","slug":"luspatercept-aamt","phase":"marketed","mechanism":"Growth/differentiation factor 11, Growth/differentiation factor 8","indications":["Myelodysplastic syndrome","beta Thalassemia"],"catalyst":""},{"name":"RPC1063","genericName":"RPC1063","slug":"rpc1063","phase":"phase_3","mechanism":"RPC1063 is a sphingosine 1-phosphate receptor modulator.","indications":["Relapsing forms of multiple sclerosis"],"catalyst":""},{"name":"RPC4046","genericName":"RPC4046","slug":"rpc4046","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Rasigiline","genericName":"Rasigiline","slug":"rasigiline","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"bb2121","genericName":"bb2121","slug":"bb2121","phase":"phase_3","mechanism":"bb2121 is a chimeric antigen receptor (CAR) T-cell therapy that redirects a patient's own T cells to recognize and kill multiple myeloma cells expressing BCMA.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"low-dose dexamethasone","genericName":"low-dose dexamethasone","slug":"low-dose-dexamethasone","phase":"marketed","mechanism":"Low-dose dexamethasone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors.","indications":["Multiple myeloma (in combination with lenalidomide and bortezomib)","Cerebral edema","Autoimmune and inflammatory conditions"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQemdHRElqa3I4aVJaWncxRGxneGJiZmh6UFozQ1VVallsOExqa0RLVjBJRnMzN3pEaExJRmQ0QWRudFpneTh3T0dpeWxnMFJSNi1TTFh3aHhKTUIxUmJYd3J4ZlZ0bHdncXZNX3g1eW9MdlpYdUZUX0swSF8zNGN2ZEwtQ1gwNjhUTU5xb01XTFpkYmMzN190LUdvZDg?oc=5","date":"2026-03-03","type":"patent","source":"Equitypandit","summary":"Natco Pharma Launched a Generic Version of Celgene’s Pomalyst in US - Equitypandit","headline":"Natco Pharma Launched a Generic Version of Celgene’s Pomalyst in US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQbktKWHd5aHNuZ0lncUU5RzNuYXdSZlhqRW9hYlVKT3JmcjB1enNCX29kUDB0Y0VsQjhYRkdkUTZVYTJGb29iY2FINnFfZks3dTFnd0ppbGRQY1NUYWxrRTRCejdsa3IwM3ZncGhQeUEtaVdzWVFwaFZtMEt4bDNXdzd2V01JUEFPeDlYQkZSNGpvYU1DS1paazVGaw?oc=5","date":"2025-10-14","type":"pipeline","source":"Fierce Pharma","summary":"Cabaletta picks up the pace with new commercial chief from Legend, Celgene - Fierce Pharma","headline":"Cabaletta picks up the pace with new commercial chief from Legend, Celgene","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNUS05cl9OazFfOThqTkVDZHk4ZG9wMVNwTnphOU9sM1dZaml1M040N0w2Yl9xZDdPTzV4c3c3MkZaTW9uWTFKRzhOZHlmbTRYY0M3UE9DTS1nWkM3MDBlaGtTMl9md3ZLUlZScWVBbTBTNk5lR01UQkxkbTVRSDZnSVkxV09XRkx5NUZwV1JhMnNRTGZDTVowcm9keHJlUQ?oc=5","date":"2022-08-01","type":"pipeline","source":"Pharma Voice","summary":"A glimpse inside Bristol Myers Squibb’s integration with Celgene - Pharma Voice","headline":"A glimpse inside Bristol Myers Squibb’s integration with Celgene","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxOWjVrOEFoLW5DTGZRaDdzOFR1MlktdGM5ODNiZG54R2FqMzdPY0V6YTZndkFlNVEwU2VlVng4OFd4X1Y2Wnh1V0RiR2xwazM2RG9xaU8xYURsY0N4R2NPQTBSLXpBcE5uaEtwOTJaZGNraUt5b0VRUkw2Zk45OTlvNlExdS0tSHN0QnJFdUJfbmQybzhOdzRmQ0tiS3NyXzJidkpUbDNkY2tfdG9BYmVnV1ZPNVh1dTJDdUNDczI2M1Q1SHdtSUJkR0FVRkJDaEU?oc=5","date":"2022-01-24","type":"patent","source":"Generics and Biosimilars Initiative","summary":"Celgene settles Revlimid patent litigation with Natco Pharma - Generics and Biosimilars Initiative","headline":"Celgene settles Revlimid patent litigation with Natco Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNWVJueUE4RlBrUXNuTTJ3cDRRbkFnSlFNSUs1d1NpVXRoV1dQNkZXMTJGcWEzMEZUVzh4amQwWmJKd3Zwb1pDOGFCbkU4b0hDVWZsLXFqTjhHYU1tdDhpb3QxNzFOSDNuZlc2bWZ6el9NQll1cEs5dEQyQkJFYlJxNDFvQjgyb1AyRkNRTGNDaVhUTXJZQWpZLUdpb1BJSzJiOE5nRUVPaw?oc=5","date":"2021-12-13","type":"deal","source":"Fierce Pharma","summary":"Bristol Myers Squibb, after massive Celgene takeover, plots $15B buyback plan - Fierce Pharma","headline":"Bristol Myers Squibb, after massive Celgene takeover, plots $15B buyback plan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPVjA1bXJySW83SkdVQTU3NDJEUFYwb1hDTlpINlVwUjc3ZkFLZ0syZW53YVItRGdjaWREWll0Q2dqWV9jOXlHQXJuOWt1aUFXYUdMZ3d6Q2Z1N3daai1sb3RXYkVPcFUwMFc3SFRwWmtMdWFEZmluWjNkVS1ncVVmQTY2bEYxNmw3ZTZyUUMxMkpFSENPZ0tHUTF6OGNoVnBfTzgyc0FQRnJrRFZXS2lZZjhGRzNBZ1VLWUxNTTV6OE5QN1Zx?oc=5","date":"2021-06-03","type":"pipeline","source":"Fierce Pharma","summary":"It had to happen: Ex-Celgene shareholders sue Bristol Myers Squibb for $6.4B in lost CVR cash, claiming 'blatant misconduct' - Fierce Pharma","headline":"It had to happen: Ex-Celgene shareholders sue Bristol Myers Squibb for $6.4B in lost CVR cash, claiming 'blatant miscond","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOaXlkbHY1VXA2YTZJUDNEMU51amtfWkE1NU1pOVhoNFhWRmZJUmxQV1lXZW1tUUoybHlqbkZGQTA4Z2tyN2JJLTRzUE5jUnZ3cXNJNWdqbl9yNFFVazhVTVcwWWZvN2VOUUdjMXdGRkQwaWRZeTROd3d6eC1ZMDBEV2dTeFRkeWhoWUdXRm02emNOUTE2aHN1ajNCQ2pnYnVRb19RT1plMkhFZ0FXWW9RUDNhMmRzQmcybUE?oc=5","date":"2020-04-13","type":"pipeline","source":"Mintz","summary":"Celgene v. Sun Pharma Global: Satisfying Subject Matter Jurisdiction Under § 271(e)(2) - Mintz","headline":"Celgene v. Sun Pharma Global: Satisfying Subject Matter Jurisdiction Under § 271(e)(2)","sentiment":"neutral"},{"date":"2020-02-10","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC: SC 13G","headline":"SC 13G Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOakFWTDdySGViUXpvTDVjYUlYWXBoZnJKbkVXcG9GTnR3MDdCb0NSYkxuVFJ3QWlQQzF2Rk9mak13aXFUckNXY05TZFlyaEs4eUtueDRVdzZzalJCX09QUDJfMG0ydy1uYWNYUEM2ckhOS0tQeWZJMl80cy0xTTZnTkppOEZBblpIX19JcXVITTJUQ0l5bWYwMVJjdW1SZUw0eGtXQzhuRkxXak5CX044?oc=5","date":"2019-11-22","type":"deal","source":"Fierce Pharma","summary":"BMS investors bet big on 3 newly acquired Celgene drugs for cancer and MS - Fierce Pharma","headline":"BMS investors bet big on 3 newly acquired Celgene drugs for cancer and MS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPbWZyZVV4OW5SMzEyWjRCWi15WnRNMEhjLXpLUDcxOXE2OVUxTmRLUVkzUWpuZkQ4OFllTHRZa0VVbDdZUEdQY3ZuMlcxYUNNMExQRlRsYmFCeld4OGtUTmIycllNeXV0aFdaTjFVTGRqRFJmS3JuT1BuVzlESTllWnZLN2hEa21y?oc=5","date":"2019-01-22","type":"pipeline","source":"statnews.com","summary":"Celgene, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing - statnews.com","headline":"Celgene, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOb3RtZTQ4Z0NuXzY5QWhoYlJzLXNoRGlfR2doUUpRZV9BRV9HVHhLRUZtbVRPSUMxSjlwRXhNTnB6SGw0NVY2U01CbFlRMmRCYmNTTHhHQ1U5MHBSeFBxZG9pTGRNQm4tOVV6V3owV2hZZXlqTmNVdmFkLUJOekJFQVdSMzVtZHV5cFVMZXRtS0ZOMHJ1bXpNazU3TjFmcWdJLXh1VldWd2J5QUN4X1h5cF9XakVjMWdzOE5rQ2s1RUdHUQ?oc=5","date":"2019-01-04","type":"deal","source":"Fierce Pharma","summary":"The BMS-Celgene merger’s Achilles heel? An earlier-than-expected Revlimid patent loss - Fierce Pharma","headline":"The BMS-Celgene merger’s Achilles heel? An earlier-than-expected Revlimid patent loss","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPMFZpTUNTOWNEYXAxWENUUVlUQUNOeFpNQkVnRTdxSlJxQVJzWFJLVjRJVU5uLVhmSmNGekp6NnBrVnNXX2lwZHVWekRGcjU4cmpBdlgySWY0Tm96SmwybnBKYURPUkZ0TmNIMG9fejZZaHBxRjVybVBKeWJhWVBacERCM0hQaEdoU2MxNUIyaEk5aHBFQXc?oc=5","date":"2019-01-03","type":"deal","source":"BioPharma Dive","summary":"Bristol-Myers to buy Celgene in industry-shaking $74B deal - BioPharma Dive","headline":"Bristol-Myers to buy Celgene in industry-shaking $74B deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNREczNm0tbThQOXRtNXI4QVlUU01YalVJckZJb2dBWE5NVUpuZEdOU1N5R1lLaXM5VXo1Nk1Iem51WTBRMWpzWUhxeVdHUkF6VlROeXRyd05vUGFjVU1SYWFoQ2hMTWl0QUd0VG1lT3BiaUE1VXdPcGFJSGJxeXZBTzRGcVNkQ1BDOTQ4dWo3bjJsQ1Y4NkpFSk9pbjEwaEZjUjZZcDM5aGdGVVZDVW9IeXFvV19wZGU0OVE?oc=5","date":"2019-01-03","type":"deal","source":"Fierce Pharma","summary":"Bristol-Myers scores first big deal of 2019 with $74B buyout of oncology bigwig Celgene - Fierce Pharma","headline":"Bristol-Myers scores first big deal of 2019 with $74B buyout of oncology bigwig Celgene","sentiment":"neutral"}],"patents":[],"drugCount":37,"phaseCounts":{"marketed":5,"phase_3":15,"phase_1":4,"phase_2":12,"discontinued":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":13003000000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":13003000000,"period":"2017-12-31"},{"value":3483000000,"period":"2017-12-31"},{"value":3287000000,"period":"2017-09-30"},{"value":3271000000,"period":"2017-06-30"},{"value":2962000000,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":121200000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":4046000000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":35480000000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}